<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.103058</article-id><article-id pub-id-type="publisher-id">ACM-34746</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200300000_74250556.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  淋巴结转移率对不同分期胃癌患者预后影响的研究进展
  Advances in Research on thePrognosis of Gastric Cancer Patients with Lymph Node Metastasis Rate
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>凯</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>小宝</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>延安大学附属医院胃肠外科，陕西 延安</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>03</month><year>2020</year></pub-date><volume>10</volume><issue>03</issue><fpage>367</fpage><lpage>372</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   胃癌是最常见的肿瘤之一。影响胃癌预后的因素很多，如淋巴管侵犯、浸润深度、分化程度、肿瘤大小、淋巴结转移等。诸多研究表明淋巴结转移率是影响胃癌预后的独立因素，淋巴结转移率可更好地评价胃癌的预后，尤其对T2、T3期。现将淋巴结转移率对不同分期胃癌的预后综述如下。 Gastric cancer is one of the most common tumors. There are many factors affecting the prognosis of gastric cancer, such as lymphatic invasion, depth of invasion, degree of differentiation, tumor size, and lymph node metastasis. Many studies have shown that lymph node metastasis rate is an independent factor affecting the prognosis of gastric cancer. Lymph node metastasis rate can better evaluate the prognosis of gastric cancer, especially in T2 and T3. The prognosis of lymph node metastasis rate for different stages of gastric cancer is summarized below.  
     
 
</p></abstract><kwd-group><kwd>胃癌，淋巴结转移率，预后, Gastric Cancer</kwd><kwd> Lymph Node Metastasis Rate</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>淋巴结转移率对不同分期胃癌患者预后影响的研究进展<sup> </sup></title><p>白凯，李小宝<sup>*</sup></p><p>延安大学附属医院胃肠外科，陕西 延安</p><p>收稿日期：2020年3月4日；录用日期：2020年3月19日；发布日期：2020年3月26日</p><disp-formula id="hanspub.34746-formula110"><graphic xlink:href="//html.hanspub.org/file/32-1571213x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>胃癌是最常见的肿瘤之一。影响胃癌预后的因素很多，如淋巴管侵犯、浸润深度、分化程度、肿瘤大小、淋巴结转移等。诸多研究表明淋巴结转移率是影响胃癌预后的独立因素，淋巴结转移率可更好地评价胃癌的预后，尤其对T2、T3期。现将淋巴结转移率对不同分期胃癌的预后综述如下。</p><p>关键词 :胃癌，淋巴结转移率，预后</p><disp-formula id="hanspub.34746-formula111"><graphic xlink:href="//html.hanspub.org/file/32-1571213x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/32-1571213x7_hanspub.png" /> <img src="//html.hanspub.org/file/32-1571213x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>中国疾病预防控制中心信息显示：自2006年至2013年胃癌死亡率增加了8.2% (从18.87/100,000增加到20.41/100,000)。男性年龄标准化死亡率(25.66/100,000至33.89/100,000)高于女性(10.72/100,000至14.79/100,000)，而农村地区的年龄标准化死亡率(19.17/100,000至26.46/100,000)高于城市区域(15.48/100,000至20.04/100,000)。30岁以下的胃癌患者年龄标准化死亡率却增长了16.2% [<xref ref-type="bibr" rid="hanspub.34746-ref1">1</xref>]；从资料显示，胃癌的发病率逐步升高且发病年龄越来越年轻。肿瘤大小、淋巴结转移数(阳性淋巴结PLN)、肿瘤的分期、组织学分化及浸润类型、深度程度等常用来评估胃癌患者的预后。然而，有研究表明，淋巴结转移率(MLR, metastatic lymph node ratio，即转移淋巴结个数与检出淋巴结总数的比值)可更好地对术后胃癌患者的治疗和预后判断 [<xref ref-type="bibr" rid="hanspub.34746-ref2">2</xref>]。</p></sec><sec id="s4"><title>2. 淋巴结转移率的概念</title><p>1997年，UICC对胃癌TNM分期中淋巴结分期标准做出了修正，将以转移淋巴结的部位与原发病灶边缘间的距离是否超过3 cm的分期方法改为以转移淋巴结个数作为淋巴结分期的标准，一直沿用至今，然而TNM分期系统不断更新，现已经更新至第8版，其N分期以转移淋巴结个数(pathologyNode, pN)进行分期，然而有临床资料研究显示，pN易受检出淋巴结总数的影响，且规定淋巴结需 ≥ 15枚，然而检出淋巴结总数与主刀医生的临床经验水平及医院病理科的整体实力息息相关。为弥补N分期易受淋巴结检出个数影响，有学者提出淋巴结转移率为基础的淋巴结分期即RN分期 [<xref ref-type="bibr" rid="hanspub.34746-ref3">3</xref>]，此分期可有效减少分期偏移的发生 [<xref ref-type="bibr" rid="hanspub.34746-ref4">4</xref>]。</p></sec><sec id="s5"><title>3. 淋巴结转移率与早期胃癌预后的关系</title><p>早期胃癌是指癌组织局限于粘膜和粘膜下层。不论其范围大小和有否淋巴结转移。随着我国经济发展和医疗水平提高，人们越来越重视身体健康，早期胃癌的检出率也相对提高，相继其预后也备受关注。Saka M. [<xref ref-type="bibr" rid="hanspub.34746-ref5">5</xref>] 等人研究表明，在早期胃癌患者中，淋巴结转移是胃癌复发的独立危险因素。复发通常是淋巴细胞，这些患者可以通过辅助化疗得到有效的治疗。Folli等 [<xref ref-type="bibr" rid="hanspub.34746-ref6">6</xref>] 等研究发现早期胃癌淋巴结转移率约为14.4%。Gunji等 [<xref ref-type="bibr" rid="hanspub.34746-ref7">7</xref>] 对一组早期胃癌术后的患者随访显示，淋巴结转移率为10.2%，发现淋巴结转移的个数与术后患者的预后影响明显，并且淋巴结转移的越远、个数越多，其预后越差。中国胃肠肿瘤外科联盟自2014年至2016年收集了全国88350例胃癌手术患者，资料分析表明早期胃癌占19.5%、局部进展期胃癌占70.8%，晚期胃癌占9.7%；其中pT1a 患者6975例(48.5%)，7402例(51.5%) PT1B患者早期胃癌的淋巴结转移率为12.7%，其中pT1a患者的淋巴结转移率为5.7%，pT1b 患者淋巴结转移率19.3% [<xref ref-type="bibr" rid="hanspub.34746-ref8">8</xref>]。李继坤等 [<xref ref-type="bibr" rid="hanspub.34746-ref9">9</xref>] 临床研究显示无淋巴结转移的患者预后明显优于有淋巴结转移的早期胃癌患者。沈历宗等 [<xref ref-type="bibr" rid="hanspub.34746-ref10">10</xref>] 等对早期胃癌患者研究表明，淋巴结的转移率与肿瘤的分化程度有关，分化良好的转移率明显较低。另外，Tanabe等 [<xref ref-type="bibr" rid="hanspub.34746-ref11">11</xref>] 对669例粘膜内癌患者进行研究，淋巴结转移率为21%，主要是未分化型癌和凹陷型癌。对于淋巴结转移的因素，Kim D.Y. [<xref ref-type="bibr" rid="hanspub.34746-ref12">12</xref>] 得出独立危险因素直径 &gt; 2.5 cm、未分化型和粘膜下癌；Pelz J. [<xref ref-type="bibr" rid="hanspub.34746-ref13">13</xref>] 明确独立危险因素与肿瘤的分化程度、直径 &gt; 2 cm有关；Kunisaki C. [<xref ref-type="bibr" rid="hanspub.34746-ref14">14</xref>] 和Skoropad V. [<xref ref-type="bibr" rid="hanspub.34746-ref15">15</xref>] 均认为浸润深度为淋巴结转移的独立危险因素。从各学着的研究表明，早期胃癌患者的淋巴结转移与癌症淋巴管侵犯、浸润深度、分化程度、肿瘤大小密切相关且早期胃癌比进展期胃癌的淋巴结转移率明显较低。</p></sec><sec id="s6"><title>4. 淋巴结转移率与各T分期胃癌预后的关系</title><p>在我国大部分患者住院治疗时已经进入T2、T3、T4期，甚至失去了手术机会。T1期患者淋巴结转移的机率小、预后较好且患者临床症状不明显。T2、T3、T4期的淋巴结转移发生率高，T2、T3期同意手术的患者较多，T4期患者肿瘤大多侵犯周围组织、远处转移的风险较高，预后较差 [<xref ref-type="bibr" rid="hanspub.34746-ref16">16</xref>]。冯润华 [<xref ref-type="bibr" rid="hanspub.34746-ref17">17</xref>] 等人对238例胃癌患者进行随访发现在T2-T3中MLR与PN的预测能力相同。任春光 [<xref ref-type="bibr" rid="hanspub.34746-ref18">18</xref>] 等人研究发现淋巴结转移率对p T2和p T3期病人的预后有较好的评估预测价值，但是对p Tl、p T4期根治术后病人的预后无统计学意义。丁俊秀 [<xref ref-type="bibr" rid="hanspub.34746-ref19">19</xref>] 等人通过对89例T3期胃癌患者进行研究后发现在清扫出足够多的淋巴结情况下，T3期胃癌MLR高低与检出淋巴结个数无相关性，MLR对T3期胃癌患者的预后无明显优势。还有研究发现对比分析淋巴结转移率、淋巴结转移个数对胃癌预后的判断，结果发现在预测T3N3期胃癌患者预后，MLR分期优于淋巴结转移个数 [<xref ref-type="bibr" rid="hanspub.34746-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.34746-ref21">21</xref>]。由此可见，淋巴结转移率有助于弥补T3期胃癌TNM分期系统中的淋巴结转移分期系统，可更好地指导T3期胃癌的手术治疗和预后的判断。李凤科 [<xref ref-type="bibr" rid="hanspub.34746-ref22">22</xref>] 等人对347例接受手术治疗的T3期胃癌患者进行研究分析后得出，淋巴结转移率是T3期胃癌独立的预后危险因素。这与国际上Kilic等 [<xref ref-type="bibr" rid="hanspub.34746-ref23">23</xref>] 认为淋巴结转移率是胃癌患者预后的独立危险因素观点是相同的，陈烽 [<xref ref-type="bibr" rid="hanspub.34746-ref24">24</xref>] 等人对215例T4a期胃癌术后患者进行研究分析发现RN分期与PN分期对患者5年生存率预测无明显差异。综上所述，淋巴结转移率是胃癌不同阶段预后的独立危险因素。在T2、T3期胃癌患者预测能力明显优于PN分期。</p></sec><sec id="s7"><title>5. 淋巴结转移率分期问题</title><p>大量研究数据表明，MLR是胃癌重要的预后指标，但目前关于MLR的分期问题，还没有明确的指南指出，不同科研机构采用的分级依据也不同，常用的分级依据有：ROC曲线上敏感度和特异度相加最大值所对应的操作点；应用log-rank生存检验的最佳分级法；Cox回归风险比差异；鞅残差分析等。为了保证分级能够更准确，有些研究中常常几种方法共同应用，然而，即使采用同一种分级方法，样本量、研究对象、或手术根治程度不同的人群里，MLR分级标准也存在差异，成为MLR临床应用的最大障碍。Saito等 [<xref ref-type="bibr" rid="hanspub.34746-ref25">25</xref>] 将RN分期分为0、1%~5%、6%~10%、11%~20%、21%~30%和&gt;30% 6组。Kunisaki [<xref ref-type="bibr" rid="hanspub.34746-ref26">26</xref>] 等收集了758例患者，将淋巴结转移率分为0、^10%、10%~20%、和^20%共四组。Bando等 [<xref ref-type="bibr" rid="hanspub.34746-ref27">27</xref>] 收集了650例检出淋巴结总数 ≥ 15枚胃癌术后患者，将RN分为0、&lt;10％、10%~25%和&gt;25% 4组。Kodera等 [<xref ref-type="bibr" rid="hanspub.34746-ref28">28</xref>] 对656例行胃癌术后患者资料，将rN分为0、1%~19%、20%~60%和&gt;60% 4组；冯润华等 [<xref ref-type="bibr" rid="hanspub.34746-ref29">29</xref>] 将淋巴结无转移、淋巴结转移率为0%~10%、10%~30%和&gt;30%三组。耿宏智等 [<xref ref-type="bibr" rid="hanspub.34746-ref30">30</xref>] 则将rN分期分为：rN0：无淋巴结转移；rNl：淋巴结转移率 &lt; 30%；rN2：淋巴结转移率 ≥ 30%但&lt;60%；rN3：淋巴结转移率 ≥ 60%。上述研究在研究样本量和肿瘤分期方面各不相同，所以无法作为淋巴结转移率的官方标准。</p></sec><sec id="s8"><title>6. 另一个新型观点的提出</title><p>近年来，国内外有学者提出阳性淋巴结对数比(log odds positive lymph nodes, LODDS)这一概念，将其定义为当检索到一个LN时，作为正LN的概率与作为负LN的概率之间的比率的对数。最新的研究表明，LODDS分类比UICC N级系统或MLR更好的预测胃癌的预后，而且它不是由小于16个除去淋巴结。T&#243;th [<xref ref-type="bibr" rid="hanspub.34746-ref31">31</xref>] 等人通过研究分析了LODDS分期系统是所有患者以及检出淋巴结^16患者预测胃癌生存的最佳因子。Agnes, A. [<xref ref-type="bibr" rid="hanspub.34746-ref32">32</xref>] 等人对1221名胃癌患者进行多中心分析研究后发现MLR和TLODDS分期系统可以补充TNM分期系统的不足。如果这一研究得到证实，TNM分期系统应考虑引入LNR或LODDS。Sun等 [<xref ref-type="bibr" rid="hanspub.34746-ref33">33</xref>] 证明使用LODDS系统比使用pN和MLR系统更可靠。Spolverato等 [<xref ref-type="bibr" rid="hanspub.34746-ref34">34</xref>] 也发现当淋巴结状态被评估为连续变量时，LODDS是生存的最佳预测因子，但当淋巴结状态被分类时，LNR成为生存的最佳预测因子。国内周志伟等 [<xref ref-type="bibr" rid="hanspub.34746-ref35">35</xref>] 人研究表明：LODDS的预测性能优于N分期及RN分期；尤其无淋巴结转移时，只有LoDDs分期有预测性能力。</p></sec><sec id="s9"><title>7. 结语</title><p>随着外科学和病理学的发展，MLR作为一种及其重要和新型的胃癌预后指标，来弥补PN分期的不足之处，是许多学者的共同心愿。首先如何制定MLR的分期问题，其次有学者将淋巴结转移率、淋巴结转移阳性比率或淋巴结转移率分期翻译为metastatic lymph node ratio，英文缩写为MLR或rN；将淋巴结转移度翻译为lymph nodes metastatic ratio和lymph noder ratio英文缩写为LNR。目前各文献中应用最多的是MLR、rN、LNR，命名上的不统一导致读者感觉混乱，有必要尽快完善统一的标准，最后国内外相继报道了LODDs分期，且对胃癌的预后与MLR相当甚至能更好地弥补TNM分期系统，希望国际尽快得到统一标准，为广大医护人员与患者带来福音。</p></sec><sec id="s10"><title>文章引用</title><p>白 凯,李小宝. 淋巴结转移率对不同分期胃癌患者预后影响的研究进展Advances in Research on thePrognosis of Gastric Cancer Patients with Lymph Node Metastasis Rate[J]. 临床医学进展, 2020, 10(03): 367-372. https://doi.org/10.12677/ACM.2020.103058</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34746-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yin, J., Song, J.N., Bai, Z.G., Zhang, Z.T., et al. (2017) Gastric Cancer Mortality Trends in China (2006-2013) Reveal Increasing Mortality in Young Subjects. Anticancer Research, 37, 4671-4679. &lt;br&gt;https://doi.org/10.21873/anticanres.11871</mixed-citation></ref><ref id="hanspub.34746-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Marchet, A., Mocellin, S., Ambrosi, A., et al. (2007) The Ratio between Metastatic and Examined Lymph Nodes (N Ratio) Is an Independent Prognostic Factor in Gastric Cancer Re-gardless of the Type of Lymphadenectomy: Results from an Italian Multicentric Study in 1853 Patients. Annals of Surgery, 245, 543-552. &lt;br&gt;https://doi.org/10.1097/01.sla.0000250423.43436.e1</mixed-citation></ref><ref id="hanspub.34746-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Marchet, A.J., Mocellin, S.J., Ambrosi, A., et al. (2008) The Prognostic Value of N-Ratio in Patients with Gastric Cancer: Validation in a Large, Multicenter Series. European Journal of Surgical Oncology, 34, 159-165. &lt;br&gt;https://doi.org/10.1016/j.ejso.2007.04.018</mixed-citation></ref><ref id="hanspub.34746-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Dang, P., Raut, C.P.J., et al. (2012) Comparison of a Lymph Node Ratio-Based Staging System with the 7th AJCC System for Gastric Cancer: Analysis of 18,043 Patients from the SEER Database. Annals of Surgery, 255, 478-485. &lt;br&gt;https://doi.org/10.1097/SLA.0b013e31824857e2</mixed-citation></ref><ref id="hanspub.34746-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Saka, M., Katai, H., Fukagawa, T., Nijjar, R. and Sano, T. (2008) Recurrence in Early Gastric Cancer with Lymph Node Metastasis. Gastric Cancer, 11, 214-218. &lt;br&gt;https://doi.org/10.1007/s10120-008-0485-4</mixed-citation></ref><ref id="hanspub.34746-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Folli, S., Morgagni, P., Roviello, F., et al. (2001) Risk Factors for Lymph Mode Metastases and Their Prognostic Significance in Early Gastric Cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGC). Journal Japanese Journal of Clinical Oncology, 31, 495-499. &lt;br&gt;https://doi.org/10.1093/jjco/hye107</mixed-citation></ref><ref id="hanspub.34746-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ounji, Y., Suzuki, T., et al. (2003) Prognostic Significance of the Number of Metastatic Lymph Nodes in Early Gastric Cancer. Digestive Surgery, 20, 148-153. &lt;br&gt;https://doi.org/10.1159/000069392</mixed-citation></ref><ref id="hanspub.34746-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王胤奎, 李子禹, 陕飞, 苗儒林, 薛侃, 李浙民, 高超, 陈楠, 高翔宇, 李沈, 季加孚. 我国早期胃癌的诊治现状——来自中国胃肠肿瘤外科联盟数据的启示[J]. 中华胃肠外科杂志, 2018, 21(2): 168-174.</mixed-citation></ref><ref id="hanspub.34746-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李继坤, 延庆, 陈进. 早期胃癌淋巴结转移规律及预后分析[J]. 中国实用外科杂志, 2002, 22(5): 284-286.</mixed-citation></ref><ref id="hanspub.34746-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">沈历宗, 黄一鸣, 孙茂才, 等. 胃黏膜下层癌淋巴结转移临床病理因素分析[J]. 中国实用外科杂志, 2009, 29(1): 91-93.</mixed-citation></ref><ref id="hanspub.34746-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tanabe, H., Washita, A., Haraoka, S., et al. (2006) Clinicopathological Characteristics of Intramucosal Gastric Carcinoma with Lymph Node Metastasis. Stomach and Intestine (Tokyo), 41, 1119-1129.</mixed-citation></ref><ref id="hanspub.34746-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D.Y., Joe, J.K., Ryu, S.Y., et al. (2004) Factors Related to Lymph Node Metastasis and Surgical Strategy Used to Treat Early Gastric Carcinoma. World Journal of Gastroenterology, 10, 737-740. &lt;br&gt;https://doi.org/10.3748/wjg.v10.i5.737</mixed-citation></ref><ref id="hanspub.34746-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Pelz, J., Merkel, S., Horbach, T., et al. (2004) Determination of Nodal Status and Treatment in Early Gastric Cancer. European Journal of Surgical Oncology, 30, 935-941. &lt;br&gt;https://doi.org/10.1016/j.ejso.2004.07.016</mixed-citation></ref><ref id="hanspub.34746-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kunisaki, C., Shimada, H., Nomura, M., et al. (2001) Appropriate Lymphnode Dissection for Early Gastric Cancer Based on Lymph Node Metastases. Surgery, 129, 153-157. &lt;br&gt;https://doi.org/10.1067/msy.2001.110222</mixed-citation></ref><ref id="hanspub.34746-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Skoropad, V., Berdov, B. and Zagrebin, V. (2005) Clinicopathological Features and Outcome of Surgical Treatment of 149 Patients with Early (pT1) Gastric Cancer. Onkologie, 28, 247-252.</mixed-citation></ref><ref id="hanspub.34746-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hyung, W.J., Noh, S.H., Yoo, C.H., et al. (2002) Prognostic Significance of Metastatic Lymph Node Ration in T3 Gastric Cancer. World Journal of Surgery, 26, 323-329. &lt;br&gt;https://doi.org/10.1007/s00268-001-0227-9</mixed-citation></ref><ref id="hanspub.34746-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">冯润华, 朱正纲, 燕敏, 陈军, 项明, 尹浩然, 林言箴. 淋巴结转移率对T2-T3期胃癌患者预后评估的价值[J]. 中华胃肠外科杂志, 2007, 10(5): 431-435.</mixed-citation></ref><ref id="hanspub.34746-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">任春光. 胃癌患者各pT期与阳性淋巴结转移率的预后关系[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2016.</mixed-citation></ref><ref id="hanspub.34746-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">于俊秀, 吴育连, 杨立涛. 淋巴结转移率评估T3期胃癌病人预后的价值[J]. 中华医学杂志, 2005, 85(13): 922-925.</mixed-citation></ref><ref id="hanspub.34746-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">刘晓文, 王亚农, 朱蕙燕, 等. 淋巴结转移阳性比率在预测T3期胃癌患者预后中的价值[J]. 中国癌症杂志, 2009, 19(5): 371-376.</mixed-citation></ref><ref id="hanspub.34746-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Feng, J., Wu, Y.F., Xu, H.M., et al. (2011) Prognostic Significance of the Metastatic Lymph Node Ratio in T3 Gastric Cancer Patients Undergoing Total Gastrectomy. Asian Pacific Journal of Cancer Prevention, 12, 3289-3292.</mixed-citation></ref><ref id="hanspub.34746-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">李凤科, 宋书彬, 薛英威. 淋巴结转移率在T3期胃癌预后中的临床意义(附347例) [J]. 现代肿瘤医学, 2019, 27(1): 87-91.</mixed-citation></ref><ref id="hanspub.34746-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kilic, N., Gundogdu, S.B., Ozden, S., et al. (2018) The Prognostic Value of Different Node Staging Systems in Patients with ≤ 15 Lymph Nodes Following Surgery for Gastric Adenocarcinoma. Acta Chirurgica Belgica, 118, 1-6. &lt;br&gt;https://doi.org/10.1080/00015458.2017.1346036</mixed-citation></ref><ref id="hanspub.34746-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">陈烽, 林建清, 黄志军, 陈志耀, 叶泽毅, 王伟东. 淋巴结转移率在评估T_(4a)期胃癌患者预后的探讨[J]. 中国卫生标准管理, 2018, 9(21): 32-35.</mixed-citation></ref><ref id="hanspub.34746-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Saito, H., Fukumoto, Y., Osaki, T., et al. (2008) Prognostic Significance of the Ratio between Metastatic and Dissected Lymph Nodes (N Ratio) Inpatients with Advanced Gastric Cancer. The Journal of Surgical Oncology, 97, 132-135. &lt;br&gt;https://doi.org/10.1002/jso.20929</mixed-citation></ref><ref id="hanspub.34746-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kunisaki, C., Shimada, H., Nomura, M., et al. (2005) Clinical Impact of Metastatic Lymph Node Ratio in Advanced Gastric Cancer. Anticancer Research, 25, 1369-1376.</mixed-citation></ref><ref id="hanspub.34746-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Bando, E., Yonemura, Y., Taniguchi, K., et al. (2002) Outcome of Ratio of Lymph Node Metastasis in Gastric Carcinoma. Annals of Surgical Oncology, 9, 775-784. &lt;br&gt;https://doi.org/10.1007/BF02574500</mixed-citation></ref><ref id="hanspub.34746-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Kodera, Y., Yamamura, Y., Shimizu, Y., et al. (1998) Lymph Node Status Assessment for Gastric Carcinoma: Is the Number of Metastatic Lymph Nodes Really Practical as a Parameter for N Categories in the TNM Classification? Tumor Node Metastasis. The Journal of Surgical Oncology, 69, 15-20. &lt;br&gt;https://doi.org/10.1002/(SICI)1096-9098(199809)69:1&lt;15::AID-JSO4&gt;3.0.CO;2-N</mixed-citation></ref><ref id="hanspub.34746-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">冯润华, 朱正纲, 燕敏, 等. 淋巴结转移率对T2-T3期胃癌患者预后评估的价值[J]. 中华胃肠外科杂志, 2007, 10(5): 431-435.</mixed-citation></ref><ref id="hanspub.34746-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">耿宏智, 刘兵, 徐艺可, 等. 影响进展期胃癌淋巴结转移率分期和转移数量分期的病理因素[J]. 中华胃肠外科杂志, 2013, 16(4): 358-362.</mixed-citation></ref><ref id="hanspub.34746-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tóth, D., Bíró, A., Varga, Z., árkosy, P., et al. (2017) Comparison of Different Lymph Node Staging Systems in Prognosis of Gastric Cancer: A Bi-Institutional Study from Hungary. Chinese Journal of Cancer Research, 29, 323-333. &lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2017.04.05</mixed-citation></ref><ref id="hanspub.34746-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Agnes, A., Biondi, A., Cananzi, F.M., Persiani, R., et al. (2019) Ratio-Based Staging Systems Are Better than the 7th and 8th Editions of the TNM in Stratifying the Prognosis of Gastric Cancer Patients: A Multicenter Retrospective Study. The Journal of Surgical Oncology, 119, 948-957. &lt;br&gt;https://doi.org/10.1002/jso.25411</mixed-citation></ref><ref id="hanspub.34746-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Z., Xu, Y., Li, D.M., et al. (2010) Log Odds of Positive Lymph Nodes: A Novel Prognostic Indicator Superior to the Number-Based and the Ratio-Based N Category for Gastric Cancer Patients with R0 Resection. Cancer, 116, 2571-2580. &lt;br&gt;https://doi.org/10.1002/cncr.24989</mixed-citation></ref><ref id="hanspub.34746-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Spolverato, G., Ejaz, A., Kim, Y., et al. (2015) Prognostic Performance of Different Lymph Node Staging Systems after Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 262, 991-998. &lt;br&gt;https://doi.org/10.1097/SLA.0000000000001040</mixed-citation></ref><ref id="hanspub.34746-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">周志伟. 不同淋巴结分期方法对于胃癌预后预测能力的研究[D]: [硕士学位论文]. 合肥: 安徽医科大学, 2018: 1-49.</mixed-citation></ref></ref-list></back></article>